<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01673698</url>
  </required_header>
  <id_info>
    <org_study_id>The REDUCE Pivotal Trial</org_study_id>
    <nct_id>NCT01673698</nct_id>
  </id_info>
  <brief_title>A Prospective, Randomized Multicenter Study to Evaluate the Safety and Efficacy of the ReShape Duo™ Intragastric Balloon System in Obese Subjects</brief_title>
  <official_title>A Prospective, Randomized Multicenter Study to Evaluate the Safety and Efficacy of the ReShape Duo™ Intragastric Balloon System in Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ReShape Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ReShape Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The REDUCE Pivotal Trial is a pivotal clinical study designed to develop valid scientific
      evidence regarding the safety and effectiveness of the ReShape Duo® as an adjunct to diet and
      exercise in the treatment of obese subjects with one or more obesity-related comorbid
      conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Treatment % Excess Weight Loss (EWL) With Control %EWL at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>An inferential test of whether the difference in the mean %EWL between the Treatment and Control groups at 24 weeks was significantly greater than a superiority margin 7.5%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Group Responder Rate Dichotomized at 25% EWL</measure>
    <time_frame>24 weeks</time_frame>
    <description>An inferential test of whether the percentage of participants in the Treatment Group with a weight loss of &gt;25% EWL at 24 weeks was significantly greater than 35%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight Loss Maintenance Six Months Following Device Removal</measure>
    <time_frame>48 weeks</time_frame>
    <description>Assess whether significantly greater than 50% of treatment subjects maintained 40% of their excess weight loss at 48 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">326</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>ReShape Duo Balloon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ReShape Duo Balloon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Comparator</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham Comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ReShape Duo balloon</intervention_name>
    <arm_group_label>ReShape Duo Balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet counseling</intervention_name>
    <arm_group_label>ReShape Duo Balloon</arm_group_label>
    <arm_group_label>Sham Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise counseling</intervention_name>
    <arm_group_label>ReShape Duo Balloon</arm_group_label>
    <arm_group_label>Sham Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients 21 to 60 years of age

          -  Body Mass Index (BMI) ≥ 30 kg/m^2 and ≤ 40 kg/m^2

          -  At least 5 years of obesity (with BMI ≥ 30)

          -  Stable weight, defined as a subject who has not gained or lost ≥ 5% of body weight in
             the 3 months preceding the screening assessment

          -  Failure to lose weight, within the 36 months preceding the screening date, after
             participation in either of the following:

               1. A medically or commercially supervised weight loss program involving regular
                  counseling regarding both diet and exercise.

               2. Use of a United States Food and Drug Administration (FDA)-approved diet drug

          -  The presence of one or more obesity-related comorbid conditions

          -  Willing and able to provide Informed Consent

          -  Willing and able to comply with study procedures and visit schedules as specified by
             the protocol

          -  If female, the patient must

               1. be postmenopausal for at least 1 year OR

               2. be surgically sterile, OR

               3. if of child bearing potential, must be practicing birth control, be willing to
                  avoid pregnancy for the year of study participation, have a negative serum
                  pregnancy test at screening, and a negative urine pregnancy test at baseline

          -  Residing within a reasonable distance from the Investigator's treating office and able
             and willing to travel to the Investigator's office to complete all routine follow-up
             visits.

        Exclusion criteria:

          -  History of and/or ongoing clinically significant conditions or disorders of the
             gastrointestinal (GI) tract

          -  Clinically significant and uncontrolled/unstable hepatic, reproductive,
             gastrointestinal, renal, hematologic, pulmonary, neurologic, psychiatric, respiratory,
             endocrine, or cardiovascular system diseases

          -  Significant acute and/or chronic infections of any kind.

          -  Severe coagulopathy, hepatic insufficiency or cirrhosis

          -  Uncontrolled or severe asthma, or any asthma requiring or likely to require inhaled
             steroid therapy during the anticipated duration of trial participation

          -  Severe obstructive sleep apnea

          -  Incompletely controlled hypothyroidism or hyperthyroidism

          -  Severe systemic disease [consistent with an ASA (American Society of Anesthesia)
             Physical Status Classification Score of 3 or greater]

          -  Eating disorders, especially binge eating

          -  Inability to walk 200 yards without assistance

          -  Known allergies to any of the device materials or accessories, i.e. silicone,
             methylene blue, corn starch

          -  Active drug or alcohol addiction within 12 months of enrollment

          -  Insulin-dependent diabetes (either Type 1 or Type 2) or a significant likelihood of
             requiring insulin treatment in the following 12 months

          -  Depressive disorder with total Beck Depression Inventory (BDI) score &gt; 16 points,
             and/or BDI affective subscale score &gt; 7 points at screening

          -  Ongoing treatment, or anticipated need for such treatment, with anticoagulants, known
             gastric irritants such as aspirin (ASA) or non-steroidal anti-inflammatory drugs
             (NSAIDs) or agents that can promote gastrointestinal bleeding, within 1 month prior to
             enrollment, or unwillingness to forego these medications during the study period

          -  Participation within 60 days of screening date in previous or ongoing clinical trial
             or current usage of an investigational drug or device

          -  Any use of an intragastric device prior to this study.

          -  Genetically caused obesity, such as Prader-Willi syndrome

          -  Any prior bariatric surgery or likely to undergo bariatric surgery during study
             follow-up period

          -  Concomitant use of, or unwillingness to avoid any use of, weight loss medications,
             weight loss supplements, weight loss herbal preparations and/or participation in any
             non-study-related organized weight loss program (commercial or medical) at any time
             during the study, including online or smart phone applications to track or modify food
             intake, exercise regimens or weight

          -  Chronic opiate use (&gt; 3 months continuous use) or likely need for opiate use during
             study participation

          -  Contraindication or allergy to, or unwillingness to use, proton pump inhibitor
             medication throughout study follow-up duration-Pregnancy, breast feeding, or intention
             of becoming pregnant during the study

          -  Any screening laboratory values outside of the normal range deemed clinically
             significant by the Investigator

          -  Anemia defined as either:

               1. Hemoglobin (Hgb) value for females of &lt; 11.0 g/dl, for males &lt; 12.0 g/dl

               2. Abnormal red cell indices and iron deficiency

          -  Smoking cessation within 3 months of study entry or plans to quit smoking during the
             study

          -  Major surgery, open biopsy or significant traumatic injury within 3 months prior to
             enrollment.

          -  History of significant adverse experience with sedation or anesthesia

          -  Serious or uncontrolled psychiatric illness or disorder that could compromise patient
             understanding of or compliance with study procedures

          -  Any condition that, in the opinion of the Investigator, would compromise the
             well-being of the patient or the study or prevent the patient from meeting or
             performing study requirements, including:

               1. Inability or unwillingness to sign the patient informed consent document.

               2. Inability to participate in all necessary study activities due to physical or
                  mental limitations.

               3. Inability or unwillingness to return for all required follow-up visits.

          -  Employees/family members of ReShape Medical® or any of its affiliates or contractors

          -  Employees/family members of the Investigator, sub-Investigators, or their medical
             office or practice, or surgical, bariatric or hospital organizations at which study
             procedures may be performed

          -  An immediate family member (by marriage or blood relationship) of another subject
             already enrolled in the REDUCE Pivotal Trial

        Endoscopic exclusion criteria:

          -  Peptic ulcerations

          -  Clinically significant hiatal hernia (&gt; 3 cm)

          -  Patulous pyloric channel

          -  Erosive esophagitis

          -  Varices

          -  Angiectasias

          -  Barrett's esophagus

          -  Esophageal stricture

          -  Gastric mass

          -  Any other subject characteristic that would prevent the successful insertion of a
             ReShape Duo™ or that in the opinion of the Investigator preclude safe use of the
             ReShape Duo™
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Lehmann, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Lehmann Consulting</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaime Ponce, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Medical Center</name>
      <address>
        <city>Dalton</city>
        <state>Georgia</state>
        <zip>30720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marquette General Surgical Weight Loss Center</name>
      <address>
        <city>Marquette</city>
        <state>Michigan</state>
        <zip>49855</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota/Department of Gastrointestinal Surgery</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System</name>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <zip>29680</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midsouth Bariatrics</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of TX Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2012</study_first_submitted>
  <study_first_submitted_qc>August 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2012</study_first_posted>
  <results_first_submitted>August 25, 2015</results_first_submitted>
  <results_first_submitted_qc>November 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 7, 2015</results_first_posted>
  <disposition_first_submitted>October 2, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>October 2, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 9, 2014</disposition_first_posted>
  <last_update_submitted>November 2, 2015</last_update_submitted>
  <last_update_submitted_qc>November 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>weight loss</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ReShape Duo Balloon</title>
          <description>ReShape Duo Balloon
ReShape Duo balloon
Diet counseling
Exercise counseling</description>
        </group>
        <group group_id="P2">
          <title>Sham Comparator</title>
          <description>Sham Comparator
Diet counseling
Exercise counseling</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ReShape Duo Balloon</title>
          <description>ReShape Duo Balloon
ReShape Duo balloon
Diet counseling
Exercise counseling</description>
        </group>
        <group group_id="B2">
          <title>Sham Comparator</title>
          <description>Sham Comparator
Diet counseling
Exercise counseling</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="187"/>
            <count group_id="B2" value="139"/>
            <count group_id="B3" value="326"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.77" spread="9.51"/>
                    <measurement group_id="B2" value="44.04" spread="10.17"/>
                    <measurement group_id="B3" value="43.88" spread="9.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="178"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.32" spread="2.84"/>
                    <measurement group_id="B2" value="35.43" spread="2.63"/>
                    <measurement group_id="B3" value="35.37" spread="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Treatment % Excess Weight Loss (EWL) With Control %EWL at Week 24</title>
        <description>An inferential test of whether the difference in the mean %EWL between the Treatment and Control groups at 24 weeks was significantly greater than a superiority margin 7.5%.</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Treatment group</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control group</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Treatment % Excess Weight Loss (EWL) With Control %EWL at Week 24</title>
          <description>An inferential test of whether the difference in the mean %EWL between the Treatment and Control groups at 24 weeks was significantly greater than a superiority margin 7.5%.</description>
          <units>percentage of EWL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1" spread="1.596"/>
                    <measurement group_id="O2" value="11.3" spread="1.881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0041</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment Group Responder Rate Dichotomized at 25% EWL</title>
        <description>An inferential test of whether the percentage of participants in the Treatment Group with a weight loss of &gt;25% EWL at 24 weeks was significantly greater than 35%.</description>
        <time_frame>24 weeks</time_frame>
        <population>By design, this trial only studied the weight loss responder rate of the Treatment Group subjects during the first 24 weeks of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Intent-to-Treat</title>
            <description>Intent-to-Treat population</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Group Responder Rate Dichotomized at 25% EWL</title>
          <description>An inferential test of whether the percentage of participants in the Treatment Group with a weight loss of &gt;25% EWL at 24 weeks was significantly greater than 35%.</description>
          <population>By design, this trial only studied the weight loss responder rate of the Treatment Group subjects during the first 24 weeks of the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Loss Maintenance Six Months Following Device Removal</title>
        <description>Assess whether significantly greater than 50% of treatment subjects maintained 40% of their excess weight loss at 48 weeks.</description>
        <time_frame>48 weeks</time_frame>
        <population>By design, this trial only studied weight loss maintenance at 48 weeks of the Treatment Group who initially received a balloon during the first 24 weeks of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Intent-to-Treat</title>
            <description>Intent-to-Treat population</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Loss Maintenance Six Months Following Device Removal</title>
          <description>Assess whether significantly greater than 50% of treatment subjects maintained 40% of their excess weight loss at 48 weeks.</description>
          <population>By design, this trial only studied weight loss maintenance at 48 weeks of the Treatment Group who initially received a balloon during the first 24 weeks of the study.</population>
          <units>percentage of participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5610</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Subjects</title>
          <description>Subjects who were randomized and received a balloon during weeks 0-24</description>
        </group>
        <group group_id="E2">
          <title>Control Subjects</title>
          <description>Subjects who were randomized to diet and exercise counseling only during weeks 0-24</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Esophageal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemmorhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Fecaloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="186" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="196" subjects_affected="165" subjects_at_risk="187"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="134" subjects_affected="104" subjects_at_risk="187"/>
                <counts group_id="E2" events="31" subjects_affected="28" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="124" subjects_affected="110" subjects_at_risk="187"/>
                <counts group_id="E2" events="33" subjects_affected="28" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="73" subjects_affected="72" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="34" subjects_affected="31" subjects_at_risk="187"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="28" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="187"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="187"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="27" subjects_affected="26" subjects_at_risk="187"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="187"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="187"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="187"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="187"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="187"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="187"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="187"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After 12 months after the clinical study report is available, the PI may publish clinical study results, subject to confidentiality agreements and sponsor approval. The PI shall provide sponsor a copy of proposed publication at least 60 days prior to submission so that sponsor may have the opportunity to protect its proprietary rights to information, inventions, or products developed under the clinical study. PI agrees to remove confidential information upon sponsor request.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There are no overall limitations and caveats.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director of Clinical Operations</name_or_title>
      <organization>ReShape Medical</organization>
      <phone>94429-6680</phone>
      <email>lfong@reshapemedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

